Format

Send to

Choose Destination
AJR Am J Roentgenol. 2011 Aug;197(2):W241-6. doi: 10.2214/AJR.10.6032.

Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.

Author information

1
Department of Radiology, Dana-Farber Cancer Institute and Melanoma Disease Center, Dana-Farber/Brigham and Women's Cancer Center, 44 Binney St, Boston, MA 02115, USA.

Abstract

OBJECTIVE:

The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab.

CONCLUSION:

Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.

PMID:
21785048
DOI:
10.2214/AJR.10.6032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center